How can a policy foster local pharmaceutical production and still protect public health? Lessons from the health–industry complex in Brazil
Bibliographic Data
| ID | 15540612 |
|---|---|
| Authors | Elize Massard Da Fonseca (0000-0003-3847-3105, Insper, corresponding author) |
| Year | 2017 |
| Volume | 13 |
| Issue | 4 |
| Pages | 489-502 |
| Publication date | 2017-11-03 |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Global Public Health (JOURNAL) |
| Journal identifiers | ISSN: 1744-1692 • E-ISSN: 1744-1706 |
| Publisher | Taylor & Francis (PUBLISHER • GB) |
| DOI | 10.1080/17441692.2017.1396354 |
| PMID | 29098942 |
| OpenAlex | W2766357824 |
| Language | EN |
| Citations received | 4 |
| References cited | 18 |
The global health community is increasingly advocating for the local production of pharmaceuticals in developing countries as a way to promote technology transfer, capacity building and improve access to medicines. However, efforts to advance drug manufacturing in these countries revive an old dilemma of fostering technological development versus granting access to social services, such as healthcare. This paper explores the case of Brazil, a country that has developed large-scale health-inspired industrial policies, but is, yet, little understood. Brazil's experience suggests that progressive healthcare bureaucrats can create innovative practices for technology and knowledge transfers. It also demonstrates that highly competitive pharmaceutical firms can collaborate with each other, if a government provides them the right incentives. Reforming regulatory policies is crucial for guaranteeing high-quality products in developing countries, but governments must play a crucial role in supporting local firms to adapt to these regulations. These findings send a strong message to global health policymakers and practitioners on the conditions to create a suitable environment for local production of medical products
Business · Developing country · Dilemma · Economic growth · Economics · Government (linguistics · Health care · Health technology · Incentive · Market economy · Production (economics · Public policy · Biotechnology and Related Fields · Health Systems, Economic Evaluations, Quality of Life · Pharmaceutical Economics and Policy · Health Policy
Evolutionary game model and simulation analysis of multi-stakeholder behaviour for promoting Braille labelling on pharmaceutical packaging in China’s legal framework
Improving access to medicines via the Health Impact Fund in India
Access to innovative medicines by pharma companies
Building effective collaboration between health systems and the life sciences industry
Qualitative Research Design
Local production of pharmaceuticals in Africa and access to essential medicines
Science and technology for wealth and health in developing countries
Federalism, the Economic-Industrial Health Care Complex and High-Cost Pharmaceutical Assistance in Brazil
The Gap Between Successful Innovation and Access to its Benefits
Re-Thinking Pharmaceutical Production in Africa; Insights from the Analysis of the Local Manufacturing Dynamics in Mozambique and Zimbabwe
Cervical cancer screening coverage in a high-incidence region
Using Ideas Strategically
Institutional change and political decision-making in the creation of the Brazilian National Health Surveillance Agency
Health Policy as Industrial Policy
| Citations per year | 0.5 |
|---|---|
| Citation span | 2018 - 2024 (7) |
| Highly cited | No |